What is the new drug for hypertrophic cardiomyopathy?
Aficamten (marketed under brand names such as Myqorzo) has been authorized as a once-daily oral cardiac myosin inhibitor designed to treat symptomatic obstructive hypertrophic cardiomyopathy. By binding to heart muscle cell proteins to reduce excessive cardiac contraction, the medication helps smooth heart pumping mechanics, lowers left ventricular outflow tract obstruction, and significantly improves exercise capacity and patient quality of life.
Related FAQs
Cytokinetics is a late-stage biopharmaceutical enterprise dedicated to discovering, developing, and commercializing muscle biology-directed medicines for treating serious cardiovascular and neuromuscular diseases.
Construction firms operating under names matching D Construction represent regional engineering, heavy civil contracting, and commercial building enterprises holding multi-million-dollar asset valuations.
Dacotah Bank is an established regional financial institution headquartered in Aberdeen, South Dakota, maintaining total consolidated assets exceeding $3.1 billion.
The stock ticker symbol CYTK represents shares of Cytokinetics, Incorporated, which is a publicly traded biopharmaceutical enterprise listed on the Nasdaq stock exchange.
Assessing whether Celsius Holdings shares are undervalued requires analyzing standard valuation multiples—such as price-to-earnings and price-to-sales ratios—relative to its historical growth rates and projected future earnings.
Wall Street equity research analysts covering Cytokinetics, Incorporated (CYTK) establish a consensus 12-month average price target of approximately $99.37 to $105.00 per share.
Cytokinetics, Incorporated (NASDAQ: CYTK) trades at $76.45 per share, supported by a robust market capitalization exceeding $10.3 billion.
Cytokinetics is a specialty cardiovascular biopharmaceutical company focused on pioneering scientific innovations in muscle biology and developing potential new medicines for patients suffering from diseases of cardiac muscle dysfunction.
Cytokinetics has developed key cardiovascular drug candidates, notably aficamten (marketed under the brand name MYQORZO), which is a cardiac myosin inhibitor designed for the treatment of adults with symptomatic obstructive hypertrophic cardiomyop...
As of July 2026, the overwhelming consensus rating for Cytokinetics is a "Buy," with a significant percentage of analysts classifying it as a "Strong Buy".
Diodes Incorporated records annual revenues scaling between USD 1.3 billion and USD 1.6 billion, positioning the company as a leading global manufacturer and supplier of high-quality discrete, analog, and semiconductor products.
The professional analyst consensus for Cytokinetics is a "Strong Buy," with virtually all covering analysts recommending that investors buy or hold the stock rather than sell.
Cytokinetics, Incorporated officially completed its initial public offering and began trading its common stock on the NASDAQ stock exchange under the ticker symbol CYTK on April 29, 2004.
No, Cytokinetics (CYTK) does not pay dividends. As a growth-focused biotechnology company, it prioritizes the reinvestment of all available capital into its research, development, and commercialization efforts.
Market analyst consensus ratings for Tetra Tech, trading under the ticker symbol TTEK, generally feature favorable buy or hold recommendations as equity researchers evaluate robust demand for environmental engineering, water management, and sustai...